Rheum Officinale Stem

Dosage for Rheum Officinale Stem is highly individualized and must be determined by an allergy specialist based on the patient's skin reactivity and clinical history. There is no 'standard' dose that applies to all patients.

Diagnostic Testing Dosage

• Prick/Puncture Test: Typically uses the most concentrated form (e.g., 1:20 w/v or 10,000-20,000 PNU/mL). A single drop is placed on the skin, and a sterile lancet is used to prick the epidermis.
• Intradermal Test: If the prick test is negative, a 100-fold to 1,000-fold dilution (e.g., 0.02 mL of a 1:1,000 dilution) may be injected into the dermis to form a small bleb.

Immunotherapy Dosage

• Build-up Phase: Treatment usually begins with a very low dose (e.g., 0.05 mL of a 1:100,000 dilution) injected subcutaneously once or twice weekly. The dose is gradually increased according to the patient's tolerance.
• Maintenance Phase: Once the 'top dose' or 'maintenance dose' is reached (often 0.5 mL of a 1:20 or 1:100 dilution), the frequency of injections is decreased to once every 2 to 4 weeks.

Rheum Officinale Stem may be used in children, but extreme caution is required.

• Age Considerations: While there is no absolute lower age limit, immunotherapy is rarely started in children under the age of 5 due to the difficulty of communicating systemic symptoms and the risk of anaphylaxis.
• Dosing: The dosing schedule for children is generally the same as for adults, but the physician may choose a more conservative build-up schedule (smaller increments) to ensure safety.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through traditional renal pathways in a way that increases toxicity. However, the patient's overall health must be stable before administration.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins is independent of liver enzyme function.

Elderly Patients

In patients over 65, the healthcare provider must carefully evaluate cardiovascular health. Older patients may be at higher risk of complications if they experience a systemic reaction (anaphylaxis) and may be taking medications (like beta-blockers) that make treating such a reaction more difficult.

Rheum Officinale Stem is never self-administered. It must be given by a healthcare professional in a clinical setting.

• Administration Site: Injections for immunotherapy are given subcutaneously (under the skin), usually in the posterior aspect of the upper arm. The site should be rotated between the left and right arms.
• Observation Period: Patients must remain in the clinic for at least 30 minutes after every injection. Most fatal or near-fatal reactions occur within this window.
• Storage: Vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep away from light.
• Activity: Avoid vigorous exercise for at least 2 hours before and after the injection, as increased blood flow can accelerate allergen absorption and increase the risk of a systemic reaction.

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed:

• 1-2 weeks late: The same dose may often be given.
• 3-4 weeks late: The dose is typically reduced to the previous successful dose.
• Over 4 weeks late: The dose may need to be significantly reduced, and the build-up phase may need to be restarted.

An 'overdose' in the context of allergenic extracts usually refers to an injection given at a concentration or volume higher than the patient's current tolerance level.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, drop in blood pressure, or abdominal cramping.
• Emergency Measures: Immediate administration of epinephrine (0.3mg IM for adults), followed by antihistamines, corticosteroids, and IV fluids. Emergency medical services (911) must be contacted immediately if a systemic reaction occurs outside the clinic.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Rheum Officinale Stem will experience some form of local reaction. These are generally not dangerous but indicate the immune system is responding to the allergen.

• Local Redness (Erythema): A pink or red area at the site of the injection or skin test. This usually appears within minutes and may last for several hours.
• Local Swelling (Wheal): A raised, firm bump at the injection site. For immunotherapy, a local reaction smaller than the size of a half-dollar (approx. 3 cm) is considered normal.
• Itching (Pruritus): Intense itching at the site of administration is very common and typically resolves within an hour.
• Tenderness: The injection site may feel slightly sore or 'bruised' for 24 hours.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter. This may require a dose adjustment for the next injection.
• Fatigue: Some patients report feeling unusually tired or 'flu-like' for a few hours after an immunotherapy session.
• Headache: A mild, transient headache may occur following the administration of the extract.
• Delayed Local Swelling: Swelling that appears 6 to 24 hours after the injection. This is a 'late-phase' allergic response.

• Generalized Urticaria: Hives appearing on parts of the body far away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Rhinitis: Sneezing, runny nose, or nasal congestion triggered by the systemic absorption of the allergen.

> Warning: Stop taking Rheum Officinale Stem and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Difficulty breathing, shortness of breath, or a 'tightness' in the chest. This may be accompanied by wheezing (a whistling sound when breathing).
• Laryngeal Edema: A feeling of a 'lump in the throat,' hoarseness, or difficulty swallowing, indicating the airway may be closing.
• Hypotension (Low Blood Pressure): Feeling dizzy, lightheaded, or fainting. This can lead to 'anaphylactic shock.'
• Tachycardia: A rapid or pounding heartbeat.
• Gastrointestinal Distress: Severe abdominal cramps, vomiting, or sudden diarrhea.
• Cyanosis: A bluish tint to the lips, face, or fingernails, indicating a lack of oxygen.

There are no known long-term 'toxic' effects of Rheum Officinale Stem on organs like the liver, kidneys, or brain. The primary long-term risk is the development of new sensitivities, though this is rare. Most long-term effects of immunotherapy are positive, leading to a permanent reduction in allergic symptoms and a decreased risk of developing asthma.

While Rheum Officinale Stem may not have a specific individual black box warning, the entire class of allergenic extracts carries a general warning regarding the risk of severe non-standardized reactions.

Summary of Warning:

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• They should only be administered by physicians who are exceptionally experienced in the treatment of systemic reactions.
• Patients must be observed for at least 30 minutes in the office after injection.
• Patients with unstable or severe asthma are at a significantly higher risk for fatal reactions.

Report any unusual symptoms to your healthcare provider. Even a 'large' local reaction should be reported, as it may be a precursor to a systemic reaction at the next dose.

Rheum Officinale Stem is a potent biological substance. Its use is restricted to diagnostic and therapeutic protocols managed by specialists. It is not a 'medication' in the traditional sense and cannot be used for the symptomatic relief of an ongoing allergic attack.

No specific FDA black box warning exists solely for Rheum Officinale Stem; however, it falls under the mandatory class warnings for all allergenic extracts. These warnings emphasize that anaphylaxis can occur at any time, even in patients who have previously tolerated the extract for years. The warning also states that the extract must be used with extreme caution in patients with asthma, as they are more likely to have a fatal outcome if a reaction occurs.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Every dose carries a risk. Patients must have access to an epinephrine auto-injector and know how to use it if a reaction occurs after leaving the clinic.
• Asthma Status: If a patient is experiencing an asthma flare-up or if their peak flow is significantly below their personal best, the injection should be postponed. Uncontrolled asthma is a major risk factor for immunotherapy-related death.
• Beta-Blocker Use: Patients taking beta-blockers (for blood pressure or glaucoma) may be resistant to the effects of epinephrine. This makes treating a systemic reaction extremely difficult. This must be discussed with the allergist.
• Infection/Illness: Injections should be avoided if the patient has a fever or a significant respiratory infection, as this can lower the threshold for a systemic allergic reaction.

• Pre-Injection Assessment: The clinician will check for any illness, new medications, or late reactions to the previous dose.
• Post-Injection Observation: A mandatory 30-minute wait in the clinic is required.
• Lung Function: For asthmatic patients, a peak flow meter or spirometry may be used before the injection to ensure the airway is stable.
• Skin Test Monitoring: During diagnostic testing, the skin is monitored for 15-20 minutes to measure the wheal and flare response.

Rheum Officinale Stem does not typically cause drowsiness. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery. Some patients may feel slightly lightheaded after a large injection, so caution is advised until the patient knows how they respond.

Alcohol consumption should be avoided on the day of an injection. Alcohol causes vasodilation (widening of the blood vessels), which can increase the speed at which the allergen enters the bloodstream, potentially increasing the risk of a systemic reaction.

Immunotherapy with Rheum Officinale Stem is typically a 3-to-5-year commitment. Stopping the treatment early may result in the return of allergic symptoms. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the 'immunological protection' will gradually fade if the maintenance phase is not completed.

> Important: Discuss all your medical conditions with your healthcare provider before starting Rheum Officinale Stem.

• Beta-Adrenergic Blockers (Beta-Blockers): While not an absolute contraindication in all cases, they are generally avoided. Drugs like propranolol, atenolol, or even timolol eye drops can block the effects of epinephrine. If a patient on a beta-blocker has anaphylaxis from Rheum Officinale Stem, the standard emergency treatment may fail.
• Non-Selective MAOIs: Monoamine oxidase inhibitors (used for depression) can interfere with the metabolism of epinephrine, leading to potentially dangerous blood pressure spikes if epinephrine is needed to treat an allergic reaction.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (like lisinopril) may be at a higher risk for more severe systemic reactions to allergenic extracts.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can potentiate the effects of adrenaline, complicating the management of a systemic reaction.

• Antihistamines: Drugs like cetirizine (Zyrtec), loratadine (Claritin), and diphenhydramine (Benadryl) must be stopped 3 to 7 days before skin testing. They block the H1 receptors, which will prevent a wheal and flare reaction even if the patient is allergic, leading to a false-negative result.
• H2 Blockers: Drugs like famotidine (Pepcid) can also slightly suppress skin test reactivity and should be discontinued before testing.
• Systemic Corticosteroids: Long-term use of high-dose prednisone may suppress the immune response to the extract, potentially reducing the efficacy of immunotherapy or masking skin test results.

• Alcohol: As mentioned, alcohol can increase the risk of a systemic reaction by increasing blood flow and allergen absorption.
• Spicy Foods: In some individuals, very spicy foods can cause 'gustatory rhinitis' or flushing, which might be confused with a mild allergic reaction to the extract.

• St. John's Wort: May interact with medications used to treat anaphylaxis.
• High-Dose Vitamin C: Some evidence suggests very high doses of Vitamin C may have a mild antihistamine effect, which could theoretically interfere with skin testing.
• Cross-Reactive Herbs: Patients allergic to Rheum Officinale may also react to supplements containing Sorrel or Buckwheat, as they belong to the same botanical family.

Rheum Officinale Stem does not interfere with standard blood chemistry or hematology tests. However, it will directly affect:

• Skin Prick Tests: Expected positive result if sensitized.
• In Vitro IgE Testing (ImmunoCAP): The presence of the extract in the body does not change the blood test result, but the blood test is used to confirm the findings of the extract testing.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Rheum Officinale Stem must NEVER be used in the following circumstances:

• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The risk of a systemic reaction and the subsequent need for epinephrine (which stresses the heart) is too great.
• Severe, Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted values are at an unacceptably high risk for fatal anaphylaxis.
• Hypersensitivity to Preservatives: Most extracts contain Phenol (0.45%) as a preservative. If a patient has a known severe allergy to phenol, the extract cannot be used.
• Inability to Communicate: Patients who cannot report symptoms (e.g., very young children or those with severe cognitive impairment) should not receive immunotherapy because they cannot alert the staff to early signs of anaphylaxis.

Conditions requiring a careful risk-benefit analysis include:

• Autoimmune Diseases: There is a theoretical concern that stimulating the immune system with allergenic extracts could worsen conditions like Lupus or Rheumatoid Arthritis.
• Malignancy: Patients with active cancer are generally not started on immunotherapy.
• Beta-Blocker Therapy: As noted, this complicates the treatment of emergency reactions.
• Pregnancy: While maintenance immunotherapy can often be continued, starting a new extract or increasing the dose is contraindicated due to the risk of fetal hypoxia during a systemic reaction.

Patients who are allergic to Rheum Officinale Stem may show cross-sensitivity to other members of the Polygonaceae family. This includes:

• Rheum rhabarbarum (Garden Rhubarb)
• Fagopyrum esculentum (Buckwheat)
• Rumex species (Sorrel and Dock)

If a patient has had a life-threatening reaction to buckwheat, the allergist will use extreme caution when testing with rhubarb stem extract.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Rheum Officinale Stem.

Rheum Officinale Stem is classified by the FDA as Pregnancy Category C.

• Risks: There is no evidence that the extract itself is teratogenic (causes birth defects). However, if the mother experiences anaphylaxis, it can cause a sudden drop in blood pressure and oxygen, leading to fetal distress or death.
• Clinical Guidance: Allergists generally do not start new immunotherapy or increase the dose during pregnancy. If a woman is already on a stable maintenance dose and is tolerating it well, the treatment may be continued at that dose or slightly reduced.

It is generally considered safe to continue Rheum Officinale Stem immunotherapy while breastfeeding. The allergenic proteins are broken down in the mother's body and do not pass into breast milk in a form that would sensitize the infant. No adverse effects on nursing infants have been documented.

• Approval: Rheum Officinale Stem is used in children for diagnostic testing.
• Immunotherapy: While effective, the decision to start a child on injections must consider their ability to cooperate with the 30-minute wait and their ability to describe symptoms like 'itchy throat' or 'chest tightness.'
• Growth: There is no evidence that allergenic extracts affect growth or development in children.

Patients over age 65 require a thorough cardiovascular screening before starting Rheum Officinale Stem.

• Risks: The elderly are more likely to have undiagnosed coronary artery disease. A systemic reaction or the epinephrine used to treat it could trigger a heart attack or stroke.
• Pharmacokinetics: While the processing of the allergen doesn't change, the 'physiological reserve' to handle a severe allergic reaction is lower in older adults.

No dosage adjustment is needed. The extract is not nephrotoxic. However, patients with end-stage renal disease (ESRD) may have altered immune responses, and the efficacy of immunotherapy in this population is not well-studied.

No dosage adjustment is needed. The liver is not primarily involved in the clearance of these biological proteins.

> Important: Special populations require individualized medical assessment.

Rheum Officinale Stem acts as an immunological modifier. At the molecular level, the extract contains specific proteins (allergens) that serve as ligands for IgE antibodies.

1. 1Sensitization Phase: In allergic individuals, B-cells have already produced IgE specific to rhubarb proteins. These IgE molecules are bound to high-affinity receptors (FcεRI) on mast cells.
2. 2Effector Phase (Testing): When the extract is introduced, the allergens cross-link the IgE/FcεRI complexes. This activates intracellular signaling (involving Lyn and Syk kinases), leading to the release of pre-formed mediators like histamine from granules.
3. 3Modulation Phase (Therapy): Repeated exposure to increasing doses of the allergen induces the production of IL-10 and TGF-beta by regulatory T-cells. This suppresses the allergic Th2 response and promotes the production of IgG4 'blocking' antibodies by B-cells.

• Dose-Response: In skin testing, there is a direct correlation between the concentration of the extract and the size of the wheal, up to a plateau point.
• Onset: Skin test reactions appear within 15-20 minutes. Immunotherapy effects take much longer, with clinical improvement typically seen after 6-12 months of treatment.
• Duration: The diagnostic effect is transient (hours). The therapeutic effect of a completed 3-5 year course can last for many years, sometimes for a lifetime.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Intradermal) |

| Protein Binding | High (to IgE and IgG antibodies) |

| Half-life | Minutes (proteins) to Weeks (immunological effect) |

| Tmax | 15-30 minutes (systemic absorption) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (as small peptides/amino acids) |

• Composition: A sterile solution of the water-soluble components of Rheum officinale stems. It contains proteins, glycoproteins, and potentially small amounts of anthraquinones (though these are primarily in the root).
• Solubility: Highly soluble in aqueous buffers.
• Preservative: Typically contains 0.45% Phenol.
• Stabilizer: May contain 50% Glycerin or Human Serum Albumin (HSA).

Rheum Officinale Stem belongs to the Allergenic Extracts class. It is grouped with other non-standardized plant extracts. It is distinct from 'Standardized Extracts' like Grass or Ragweed, which have federally mandated potency units.